Categories
Blood Cancer

The impact of the approval of cilta-cel in multiple myeloma [Video]

The impact of the approval of cilta-cel in multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, talks on chimeric antigen receptor T-cell (CAR-T) therapies in multiple myeloma, commenting on the recent approval of ciltacabtagene autoleucel (cilta-cel). The first CAR-T product was approved in pediatric and young adult patients with acute lymphoblastic leukemia (ALL), and its use was later expanded to treat a larger number of indications. The first CAR-T product in multiple myeloma, idecabtagene vicleucel, was approved in 2021 based on the results of the KarMMa trial (NCT03361748). More recently, the highly promising results from the CARTITUDE-1 trial (NCT03548207) led to the approval of cilta-cel by the FDA. According to Prof. Mohty, the addition of cilta-cel to the treatment armamentarium in multiple myeloma will undoubtedly improve the outcomes of patients with R/R disease, and he believes that CAR-Ts will start being used in earlier lines of treatment. Several trials are already comparing CAR-T products versus existing standards of care (SOC) in myeloma. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Watch/Read More
Categories
Blood Cancer

The role of selinexor in the treatment of multiple myeloma [Video]

In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of selinexor in the treatment of multiple myeloma, emphasizing its value in patients with del(17p)-positive relapsed/refractory (R/R) disease. Dr Richardson also highlights some of the challenges associated with the use of selinexor, and clinical trials evaluating the safety and efficacy of this agent. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Categories
Blood Cancer

New ProPublica investigation reveals racist environmental "sacrifice zones" [Video]

In a new investigation, ProPublica reporters Lylla Younes, Ava Kofman, Al Shaw, Lisa Song, and Maya Miller used EPA data processing software to examine the spread of cancer-causing chemicals and other hazardous air pollutions in communities across the United States. At the maps intimate scale, its possible to see up close how a massive chemical

Categories
Blood Cancer

How Long will a Patient Remain in the Hospital after CAR-T Reinfusion? [Video]

HealthTree University, provided by the HealthTree Foundation, offers a comprehensive online multiple myeloma curriculum with lessons, quizzes and course discussion. Learn for free at https://www.healthtree.org. Topics covered include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much more. We've partnered with over 100 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.Follow HealthTree:Twitter: https://www.twitter.com/healthtreeformmFacebook: https://www.facebook.com/healthtreeformultiplemyelomaInstagram: https://www.instragram.com/healthtreeformultiplemyeloma